Societal Implications of Medical Insurance Coverage for Imatinib as First-Line Treatment of Chronic Myeloid Leukaemia in China: A Cost Effectiveness Analysis

S Chen; C Dong; G Sheng; R Zhang; M Miao; D Wu; T Xiong; SC Tan; C Liu

doi:10.1016/j.jval.2016.08.309

Societal Implications of Medical Insurance Coverage for Imatinib as First-Line Treatment of Chronic Myeloid Leukaemia in China: A Cost Effectiveness Analysis

Value in Health ◽

10.1016/j.jval.2016.08.309 ◽

2016 ◽

Vol 19 (7) ◽

pp. A882

Author(s):

S Chen ◽

C Dong ◽

G Sheng ◽

R Zhang ◽

M Miao ◽

...

Keyword(s):

Cost Effectiveness ◽

Chronic Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Insurance Coverage ◽

Medical Insurance ◽

Societal Implications ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis

Journal of Medical Economics ◽

10.1080/13696998.2016.1271336 ◽

2017 ◽

Vol 20 (4) ◽

pp. 371-381 ◽

Cited By ~ 2

Author(s):

Guangying Sheng ◽

Suning Chen ◽

Chaohui Dong ◽

Ri Zhang ◽

Miao Miao ◽

...

Keyword(s):

Cost Effectiveness ◽

Chronic Myeloid Leukemia ◽

Myeloid Leukemia ◽

Insurance Coverage ◽

Medical Insurance ◽

Societal Implications ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Cost Effectiveness of Imatinib Compared with Interferon-?? or Hydroxycarbamide for First-Line Treatment of Chronic Myeloid Leukaemia

PharmacoEconomics ◽

10.2165/00019053-200523050-00010 ◽

2005 ◽

Vol 23 (5) ◽

pp. 515-526 ◽

Cited By ~ 30

Author(s):

Kim Dalziel ◽

Ali Round ◽

Ruth Garside ◽

Ken Stein

Keyword(s):

Cost Effectiveness ◽

Chronic Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text

Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis

Health Technology Assessment ◽

10.3310/hta8280 ◽

2004 ◽

Vol 8 (28) ◽

Cited By ~ 30

Author(s):

K Dalziel ◽

A Round ◽

K Stein ◽

R Garside ◽

A Price

Keyword(s):

Systematic Review ◽

Cost Effectiveness ◽

Chronic Myeloid Leukaemia ◽

Economic Analysis ◽

Myeloid Leukaemia ◽

Chronic Phase ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain

ClinicoEconomics and Outcomes Research ◽

10.2147/ceor.s302097 ◽

2021 ◽

Vol Volume 13 ◽

pp. 263-277

Author(s):

Maria Mareque ◽

Pau Montesinos ◽

Patricia Font ◽

José María Guinea ◽

Adolfo de la Fuente ◽

...

Keyword(s):

Cost Effectiveness ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Gemtuzumab Ozogamicin ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment ◽

Acute Myeloid

Download Full-text

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]

ClinicoEconomics and Outcomes Research ◽

10.2147/ceor.s328284 ◽

2021 ◽

Vol Volume 13 ◽

pp. 645-646

Author(s):

Maria Mareque ◽

Pau Montesinos ◽

Patricia Font ◽

José María Guinea ◽

Adolfo de la Fuente ◽

...

Keyword(s):

Cost Effectiveness ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Gemtuzumab Ozogamicin ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment ◽

Acute Myeloid

Download Full-text

Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK

PharmacoEconomics - Open ◽

10.1007/s41669-021-00278-3 ◽

2021 ◽

Author(s):

T. Alexander Russell-Smith ◽

James Brockbank ◽

Carla Mamolo ◽

Christopher Knight

Keyword(s):

Cost Effectiveness ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Gemtuzumab Ozogamicin ◽

Line Treatment ◽

First Line ◽

The Uk ◽

First Line Treatment ◽

Acute Myeloid

Download Full-text

Cost-Effectiveness Analysis Of Panitumumab + Folfox Compared To Cetuximab + Folfiri As First-Line Treatment For Patients With Wild-Type (Wt) Ras (Exons 2, 3, And 4 Of Kras And Nras) Metastatic Colorectal Cancer (Mcrc) In Colombia

Value in Health ◽

10.1016/j.jval.2015.09.1188 ◽

2015 ◽

Vol 18 (7) ◽

pp. A460 ◽

Cited By ~ 2

Author(s):

J Vargas-Valencia ◽

J Garcia Perlaza

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Metastatic Colorectal Cancer ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

Journal of Medical Economics ◽

10.1080/13696998.2017.1285780 ◽

2017 ◽

Vol 20 (6) ◽

pp. 574-584 ◽

Cited By ~ 3

Author(s):

Fernando Rivera ◽

Manuel Valladares ◽

Salvador Gea ◽

Noemí López-Martínez

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Metastatic Colorectal Cancer ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Cost-Effectiveness Analysis Comparing FOLFIRINOX and Nab-Paclitaxel (Abaraxane) Plus Gemcitabine For First-Line Treatment Of Patients with Metastatic Pancreatic Cancer from the US Societal Perspective

Value in Health ◽

10.1016/j.jval.2016.03.1607 ◽

2016 ◽

Vol 19 (3) ◽

pp. A153

Author(s):

W Cheng ◽

JW Hay

Keyword(s):

Pancreatic Cancer ◽

Cost Effectiveness ◽

Societal Perspective ◽

Cost Effectiveness Analysis ◽

Metastatic Pancreatic Cancer ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

The Us ◽

First Line Treatment

Download Full-text

Commentary on: A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder

International Urogynecology Journal ◽

10.1007/s00192-018-3662-y ◽

2018 ◽

Vol 29 (8) ◽

pp. 1221-1221

Author(s):

Abdelmageed Abdelrahman

Keyword(s):

Cost Effectiveness ◽

Overactive Bladder ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

Onabotulinumtoxin A ◽

First Line Treatment

Download Full-text